Non-alcoholic steatohepatitis
- 1 November 2004
- journal article
- duplicate publication
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 16 (11) , 1079-1085
Abstract
Non-alcoholic steatohepatitis (NASH) is an underdiagnosed liver disease characterized by steatosis, necroinflammation and fibrosis. This disease may eventually develop into cirrhosis and hepatocellular carcinoma. NASH is highly prevalent among obese individuals and among patients with diabetes mellitus type 2. Non-alcoholic fatty liver (NAFL), a precursor of NASH, is the main cause of elevated serum liver enzymes among the general population. In NASH the liver is programmed to lipogenesis rather than to glycogenesis and herein insulin-resistance plays a major role. Gradual weight loss, physical exercise and drugs that improve insulin sensitivity are potential therapies.Keywords
This publication has 70 references indexed in Scilit:
- Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance?Expert Opinion on Therapeutic Targets, 2004
- Fibrogenic impact of high serum glucose in chro nic hepatitis CJournal of Hepatology, 2003
- Impairment of Hepatic Microcirculation in Fatty LiverMicrocirculation, 2003
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through a partially conserved peroxisome proliferator-responsive elementBiochemical Journal, 2003
- PEROXISOMALβ-OXIDATION ANDPEROXISOMEPROLIFERATOR–ACTIVATEDRECEPTORα: An Adaptive Metabolic SystemAnnual Review of Nutrition, 2001
- Alcoholic fatty liver differentially induces a neutrophil-chemokine and hepatic necrosis after ischemia-reperfusion in ratHepatology, 2000
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Chenodeoxycholic Acid and Ursodeoxycholic Acid Effects in Endogenous Hypertriglyceridemias. A Controlled Double‐Blind TrialThe Journal of Clinical Pharmacology, 1981